CNS Drug Reviews, Vol. 4, No. 3, Fall 1998
نویسندگان
چکیده
The 21st annual meeting of the Canadian College of Neuropsychopharmacology (CCNP) was marked by participation of an unprecedented number of registrants > 200, comprising psychiatrists, pharmacologists, and neuroscientists from Canada and the U.S.A. The presentations consisted of four plenary lectures, three award lectures, eight symposia, and 97 posters. The major themes in the meeting included schizophrenia, Alzheimers, substance dependence, affective disorder, pain, personality disorder, neural growth and degeneration, and pharmacogenetics. A special symposium entitled Molecular Approaches to Neural Dysfunction organized with the Canadian Association for Neuroscience highlighted the recent advances in the molecular basis of neurodegenerative diseases and mechanisms of neural growth. The scientific sessions were preceded by a public lecture, organized by the CCNP and given by J. Rapoport (NIMH, Bethesda), on attention deficit hyperactivity disorder.
منابع مشابه
CNS Drug Reviews
Flupirtine is a centrally acting non-opioid analgesic; it has been in clinical use since 1984. The pharmacological and therapeutic properties of flupirtine in pain states have been reviewed extensively (7). The present review addresses new and challenging data that have been published during recent years. In particular, it has been discovered that flupirtine, in a clinically relevant dosage ran...
متن کاملCNS Drug Reviews, Vol. 4, No. 3, Fall 1998
The recent approvals of Betaseron, Avonex, and Copaxone have improved treatment options for multiple sclerosis (MS), but these therapeutics delay the progression of disease in only ~30% of the patient population. There remains an unmet need for MS therapeutics, and several new drugs enter clinical testing each year in an attempt to meet this need (37,38). This review summarizes the development ...
متن کاملCNS Drug Reviews, Vol. 4, No. 3, Fall 1998
M. Csejtei et al. (Gedeon Richter Ltd., Budapest, Hungary) reported pharmacological studies with RGH-2716 (8-{4,4-bis(4-fluorophenyl)butyl}-3-1,1-dimethylethyl)-4-methylene-1-oxa-3,8-diazaspiro{4,5}decan-2-one), known also as TDN-345. This drug was reported to protect ischemic brain tissue from energy loss in mice at doses ranging from 3 to 30 mg/kg i.p. At 0.1 to 10 μM it blocked veratridine-i...
متن کاملCNS Drug Reviews, Vol. 4, No. 4, Winter 1998
The discovery of zonisamide (ZNS) did not result from a search for new antiepileptic drug (AED). A continuous random screening for anticonvulsant activity had been in progress for many years at the research laboratories of Dainippon Pharmaceutical Co., Ltd. ZNS was discovered by serendipity in 1974 during routine testing of 1,2-benzisoxazole derivatives which were synthesized for the management...
متن کاملCNS Drug Reviews
Selective serotonin reuptake inhibitors (SSRIs) were developed with the idea of removing from the pharmacological profile of tricyclic antidepressants (TCA) all of the activities which were thought to be responsible for their adverse effects. Thus interactions with the muscarinic cholinergic receptor, the histamine receptor, and the α1 adrenoceptor were avoided. In addition, the ability to inhi...
متن کامل